Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Camrelizumab is named as a drug or biological intervention in 61 clinical trials in our China trial register, 41 of which are recruiting. Lead sponsors include Fudan University (6), Sun Yat-sen University (6) and Tongji Hospital (3). Registered phases: Phase 2, Phase 3, Phase 1/2, Phase 2/3, Not applicable, Observational and Phase 4. Conditions studied include Nasopharyngeal Carcinoma; Cervical Cancer; Hepatocellular Carcinoma.

Clinical trials of Camrelizumab

61 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT04944914	Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
NCT05613478	Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma, Immunotherapy, Preoperative	Phase 3	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
NCT05760378	Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. (ClinicalTrials.gov ↗) Triple-Negative Breast Cancer	Phase 3	Recruiting	Fudan University	China
NCT05772208	Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Recruiting	Fudan University	China
NCT05789043	Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma (ClinicalTrials.gov ↗) Acral Melanoma	Phase 3	Recruiting	Peking University Cancer Hospital & Institute	China
NCT05798793	Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Oral Squamous Cell Carcinoma	Phase 3	Recruiting	Hospital of Stomatology, Wuhan University	China
NCT05854849	Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Recruiting	Sun Yat-sen University	China
NCT06438627	Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 3	Recruiting	XIANG YANQUN	China
NCT06889688	Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer Stage IV, Triple -Negative Breast Cancer	Phase 3	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
NCT06288373	Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC (ClinicalTrials.gov ↗) Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy	Phase 2/3	Recruiting	Tongji Hospital	China
NCT06796803	Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) (ClinicalTrials.gov ↗) Potentially Resectable Hepatocellular Carcinoma	Phase 2/3	Recruiting	Shanghai Zhongshan Hospital	China
NCT04070040	Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) (ClinicalTrials.gov ↗) Primary Central Nervous System Lymphoma	Phase 2	Recruiting	Beijing Sanbo Brain Hospital	China
NCT04299581	Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	Fudan University	China
NCT04888429	Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (ClinicalTrials.gov ↗) Sarcomatoid Carcinoma of Lung	Phase 2	Recruiting	Qian Chu	China
NCT05069857	Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients (ClinicalTrials.gov ↗) Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
NCT05139095	Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (ClinicalTrials.gov ↗) Gestational Trophoblastic Neoplasia	Phase 2	Recruiting	Peking Union Medical College Hospital	China
NCT05447702	Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (ClinicalTrials.gov ↗) Triple Negative Breast Cancer	Phase 2	Recruiting	West China Hospital	China
NCT05576389	Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study (ClinicalTrials.gov ↗) Germline BRCA-mutated HER2-negative Breast Cancer	Phase 2	Recruiting	Peking University People's Hospital	China
NCT05624099	Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. (ClinicalTrials.gov ↗) Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms	Phase 2	Recruiting	Fujian Cancer Hospital	China
NCT05761470	Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation (ClinicalTrials.gov ↗) Her-2 Negative Breast Cancer, HRR Gene Mutation	Phase 2	Recruiting	Ying Lin	China
NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (ClinicalTrials.gov ↗) Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
NCT06176885	Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer	Phase 2	Recruiting	yue junhan	China
NCT06241807	Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC (ClinicalTrials.gov ↗) IMMUNOTHERAPY, Neoadjuvant Therapy, Resectable Lung Non-Small Cell Carcinoma	Phase 2	Recruiting	Shandong Cancer Hospital and Institute	China
NCT06288360	Neoadjuvant Immunochemotherapy in PD-L1-negative LACC (ClinicalTrials.gov ↗) Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative	Phase 2	Recruiting	Tongji Hospital	China
NCT06289062	Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer (ClinicalTrials.gov ↗) Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation	Phase 2	Recruiting	Tongji Hospital	China
NCT06360042	Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC (ClinicalTrials.gov ↗) Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
NCT06363825	A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Advanced Hepatocellular Carcinoma	Phase 2	Recruiting	Fujian Medical University	China
NCT06413992	Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer (ClinicalTrials.gov ↗) Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
NCT06435260	Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
NCT06561308	Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer (ClinicalTrials.gov ↗) Endometrioid Endometrial Cancer	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
NCT06869226	A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer (ClinicalTrials.gov ↗) Esophageal Cancer	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
NCT07167160	Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (ClinicalTrials.gov ↗) Cervical Cancer, Immunochemotherapy	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
NCT07238881	Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment (ClinicalTrials.gov ↗) Hepatocellulcar Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
NCT07328009	A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepato Cellular Carcinoma (HCC)	Phase 2	Recruiting	Fudan University	China
NCT07334483	A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC (ClinicalTrials.gov ↗) HCC	Phase 2	Recruiting	GrandPharma (China) Co., Ltd.	China
NCT07787273	Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Camrelizumab	Phase 2	Recruiting	Hefei Cancer Hospital of the Chinese Academy of Sciences	China
NCT04481763	A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast (ClinicalTrials.gov ↗) Triple-Negative Breast Cancer	Phase 1/2	Recruiting	Jiangxi Provincial Cancer Hospital	China
NCT05218889	Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer	Phase 1/2	Recruiting	Chinese PLA General Hospital	China
NCT06376721	Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma (ClinicalTrials.gov ↗) Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma	Phase 1/2	Recruiting	Beijing Tongren Hospital	China
NCT06485271	A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer (ClinicalTrials.gov ↗) Gastric Cancer, RWS, PD-1 Immunotherapy	Observational	Recruiting	Changzhi People's Hospital Affiliated to Changzhi Medical College	China
NCT06061276	bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC (ClinicalTrials.gov ↗) Liver Diseases, Hepatocellular Carcinoma, Immunotherapy	Not applicable	Recruiting	Sun Yat-sen University	China
NCT07790419	A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion (ClinicalTrials.gov ↗) Liver Cancer	Phase 4	Not yet open	Zhai Wenlong	China
NCT05610332	Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes (ClinicalTrials.gov ↗) Locally Advanced Gastric Cancer	Phase 3	Not yet open	Fujian Medical University	China
NCT06423937	Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer	Phase 2	Not yet open	Fudan University	China
NCT06731153	JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC (ClinicalTrials.gov ↗) Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer	Phase 2	Not yet open	Fudan University	China
NCT06759090	Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Metastatic Pancreatic Carcinoma	Phase 2	Not yet open	Zhejiang University	China
NCT07159217	Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib	Phase 2	Not yet open	Peking Union Medical College Hospital	China
NCT07521605	Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer (ClinicalTrials.gov ↗) Rectal Cancer Patients	Phase 2	Not yet open	Guangdong Provincial People's Hospital	China
NCT04616040	A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer (ClinicalTrials.gov ↗) Esophageal Cancer	Observational	Not yet open	Peking University	China
NCT07466901	A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer (ClinicalTrials.gov ↗) Cervical Cancer, Radical Surgery, Adjuvant Therapy	Not applicable	Not yet open	Jin LI	China
NCT07312578	Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma	Phase 2	By invitation	Peking University	China
NCT04639180	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (ClinicalTrials.gov ↗) Hepatocellular Carcinoma (HCC)	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
NCT05043688	Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. (ClinicalTrials.gov ↗) Resectable Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Zhigang Li	China
NCT05198609	Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial (ClinicalTrials.gov ↗) Hepatocellular Carcinoma	Phase 3	Active, closed	Sun Yat-sen University	China
NCT04521153	Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy	Phase 2/3	Active, closed	Shanghai Zhongshan Hospital	China
NCT04067037	Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (ClinicalTrials.gov ↗) Classical Hodgkin Lymphoma	Phase 2	Active, closed	Henan Cancer Hospital	China
NCT04515615	Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) (ClinicalTrials.gov ↗) Gastric Cancer Stage III	Phase 2	Active, closed	Yu jiren	China
NCT05524168	SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
NCT05602935	Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Stomach Neoplasms, Digestive System Neoplasms, Neoplasms	Phase 2	Active, closed	The Second Affiliated Hospital of Fujian Medical University	China
NCT07471815	Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (ClinicalTrials.gov ↗) Breast Cancer Triple Negative Breast Cancer	Phase 2	Active, closed	Harbin Medical University	China
NCT07791602	Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer (ClinicalTrials.gov ↗) Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

85 conditions

Condition (as registered)	Trials
Nasopharyngeal Carcinoma	5
Cervical Cancer	5
Hepatocellular Carcinoma	4
Neoadjuvant Chemoimmunotherapy	3
Immunotherapy	3
Digestive System Neoplasms	2
Colorectal Cancer	2
Triple-Negative Breast Cancer	2
Pancreatic Cancer	2
Camrelizumab	2
Neoadjuvant Therapy	2
Oral Squamous Cell Carcinoma	2
Esophageal Cancer	2
Locally Advanced Cervical Cancer	2
Stomach Neoplasms	1
Neoplasms	1
Digestive System Diseases	1
Hepato Cellular Carcinoma (HCC)	1
Primary Central Nervous System Lymphoma	1
Locally Advanced Gastric Cancer	1
Her-2 Negative Breast Cancer	1
HRR Gene Mutation	1
Fertility Preservation	1
Biliary Tract Cancer	1
Disitamab Vedotin	1
Lenvatinib	1
Immune Checkpoint Inhibitors	1
Hepatocellulcar Carcinoma	1
Hepatocellular Carcinoma (HCC)	1
Sarcomatoid Carcinoma of Lung	1
Metastatic Pancreatic Carcinoma	1
Triple Negative Breast Cancer	1
Endometrioid Endometrial Cancer	1
HCC	1
Salivary Gland Carcinoma	1
Precision Therapy	1
Radical Surgery	1
Adjuvant Therapy	1
Breast Cancer Triple Negative Breast Cancer	1
Liver Diseases	1

+ 45 more conditions in the trial records above.

Trials by country register

Register	Camrelizumab trials
Clinical trials in China	61

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Camrelizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Camrelizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Camrelizumab

Clinical trials of Camrelizumab

Conditions studied

Sponsors

Trials by country register

How this page is built